...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Analysis of skin disposition of flurbiprofen after topical application in hairless rats.
【24h】

Analysis of skin disposition of flurbiprofen after topical application in hairless rats.

机译:在无毛大鼠中局部应用氟比洛芬后的皮肤处置分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Cutaneous disposition of topically applied flurbiprofen (FP) was evaluated using a new in situ experimental model in hairless rats. A disk-shaped agar gel (3.85 cm in diameter and 0.5 cm in thickness) was subcutaneously implanted in the abdominal region of rats as a drug receptor, and a drug donor cell was subsequently placed above this agar gel. No significant pharmacokinetic modification of FP was observed as a result of this experimental procedure. A bolus injection and a constant intravenous infusion of FP were applied to the rats, followed by an analysis of FP levels in the plasma and agar gels. Using these results, the clearance rate of FP from the systemic circulation to the gel could be calculated. FP (1% gel formulation, 1.0 g/3.14 cm(2)) was then topically applied to the skin of these rats. From these experiments, the amount of FP that migrated from the formulation to the systemic circulation and the amount of FP that migrated directly to the agar gel across the skin, over 10 h, were separately evaluated to be 235.4 and 2.0 microg, respectively. Thus, most of the FP was absorbed into the systemic circulation. The effect of endogeneous vasoactive compounds and penetration enhancers on the FP disposition within skin was also determined. Epinephrine and bradykinin were used as vasoactive compounds that were entrapped in agar gel, and an isopropyl myristate system (IPM system) and a l-menthol-ethanol-glycerin-water system (MEGW system) were used as enhancers in the formulation. Epinephrine enhanced the direct delivery of FP into the agar gel to more than ten times its former level, in spite of the fact that it had no effect on systemic delivery. Bradykinin strengthened systemic delivery slightly, without changing the quantity of FP in the gel. IPM increased only the systemic delivery of FP, as was the case with bradykinin, whereas the MEGW system markedly increased both the blood concentration and the quantity of FP in the gel (13 and 200 times, respectively). This technique has proven to be an effective tool for the quantitative evaluation of cutaneous disposition of a topically applied drug.
机译:使用新的原位实验模型在无毛大鼠中评估了局部应用氟比洛芬(FP)的皮肤处置。将盘状琼脂凝胶(直径3.85cm,厚度0.5cm)皮下植入作为药物受体的大鼠腹部区域,随后将药物供体细胞置于该琼脂凝胶上方。由于该实验程序,未观察到FP的显着药代动力学修饰。给大鼠推注并连续静脉内注射FP,然后分析血浆和琼脂凝胶中的FP水平。利用这些结果,可以计算出FP从全身循环到凝胶的清除率。然后将FP(1%凝胶制剂,1.0 g / 3.14 cm(2))局部施用于这些大鼠的皮肤。从这些实验中,在10小时内,从制剂迁移至全身循环的FP量和直接经皮肤迁移至琼脂凝胶的FP量分别评估为235.4和2.0 microg。因此,大部分FP被吸收到全身循环中。还确定了内源性血管活性化合物和渗透促进剂对皮肤内FP分布的影响。肾上腺素和缓激肽被用作包埋在琼脂凝胶中的血管活性化合物,肉豆蔻酸异丙酯系统(IPM系统)和1-薄荷醇-乙醇-甘油-水系统(MEGW系统)被用作制剂中的增强剂。尽管肾上腺素对全身递送没有影响,但肾上腺素仍将FP直接进入琼脂凝胶的能力提高到其以前水平的十倍以上。缓激肽在不改变凝胶中FP量的情况下,略微增强了全身递送。与缓激肽一样,IPM仅增加了FP的全身递送,而MEGW系统显着增加了凝胶中的血液浓度和FP量(分别为13倍和200倍)。事实证明,该技术是定量评估局部用药的皮肤处置的有效工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号